Everpar Advisors LLC Sells 77 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Everpar Advisors LLC decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,515 shares of the medical research company’s stock after selling 77 shares during the quarter. Everpar Advisors LLC’s holdings in IQVIA were worth $298,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Nordea Investment Management AB boosted its holdings in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the period. Simplify Asset Management Inc. boosted its stake in IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after purchasing an additional 3,894 shares during the period. Versor Investments LP acquired a new position in IQVIA in the 3rd quarter valued at $1,328,000. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Finally, CIBC Asset Management Inc boosted its position in shares of IQVIA by 3.3% in the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock valued at $62,501,000 after acquiring an additional 8,490 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on IQV shares. Evercore ISI lowered their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. BTIG Research reduced their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, The Goldman Sachs Group decreased their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $255.82.

IQVIA Stock Performance

Shares of IQVIA stock opened at $197.25 on Friday. The company’s 50 day moving average price is $200.09 and its two-hundred day moving average price is $221.19. The firm has a market capitalization of $35.80 billion, a P/E ratio of 25.89, a P/E/G ratio of 2.09 and a beta of 1.48. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.